What are Clinical Trials?

Clinical trials are studies that test new medications in people. Doctors use clinical trials to discover new treatments for diseases. New treatments are possible only through the voluntary participation of patients and family members. Research and Clinical Trials opportunities may be available.

CELIA

Study Title: A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age (CELIA)

Purpose:

The CELIA study is a phase 2, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of BIIB080 in patients with mild cognitive impairment or mild Alzheimer’s disease dementia. BIIB080 is an anti-sense oligonucleotide that prevents translation of the tau protein, a protein that is correlated with neuronal loss and cognitive decline. Participants would be assigned to one of 3 different doses or placebo intrathecally every 12 weeks.

Duration: 2 years, including a series of screening visits and safety follow-up.

Requirements to participate in the study include:

  • Age: 50-80 years old, inclusive
  • Have a diagnosis of MCI (mild cognitive impairment) or mild Alzheimer’s disease.
  • Consent to APOE genotyping.

(Principal Investigator: Maryam Beigi, MD, Easton Center’s Katherine and Benjamin Kagan Alzheimer’s Disease Treatment Development Program))

Contact: Lorena Macias at (310) 794-6191 or send an email to LorenaMacias@mednet.ucla.edu to participate in this study or for more information.

More information on the CELIA study is available at clinicaltrials.gov ID#: NCT05399888.

PDF Flyer  


SUVEN

Study Title: SUVEN-502 Study

Purpose:

Individuals with Alzheimer's Disease are invited to participate in SUVEN-502 to determine the effectiveness of oral masupirdine, a medication targeting the serotonin system, and its ability to treat agitation associated with dementia of the Alzheimer's type compared to oral placebo. The study is 20 weeks long. In total, there will be 7 visits. Subjects will receive psychosocial support, undergo medical history, questionnaires/interviews related to agitation symptoms, cognitive assessments in addition to taking the oral medication and medication monitoring. Subjects will also need a study partner to participate in the study with them throughout the entire study.

(Principal Investigator: Pauline Wu, DO, Easton Center’s Katherine and Benjamin Kagan Alzheimer’s Disease Treatment Development Program)

Contact: Lorena Macias at (310) 794-6191 or send an email to LorenaMacias@mednet.ucla.edu to participate in this study or for more information.

More information on the SUVEN study is available at clinicaltrials.gov ID#: NCT05397639.